Quiz – Medicom Eduction

What do you know about CAR-T Cell Therapy?

1 / 5

The 63rd American Society of Hematology (ASH) Annual Meeting reported a series of breakthroughs in chimeric antigen receptor T-cell (CAR-T) therapy for the second-line treatment of relapsed/refractory diffuse B-cell lymphoma. Which of the following statements is true?

CAR-T cell therapies could replace stem cell transplants in the second line

The manner of leukapheresis and conditioning chemotherapy did not affect outcomes

The “vein-to-vein” time (from leukapheresis to CAR-T infusion) was not relevant for outcomes

New safety signals were observed in the second-line setting versus the third-line setting

2 / 5

True or False? Older patients (>65 years old) with diffuse large B cell lymphoma have poorer outcomes after CAR-T cell therapy.

True

False

3 / 5

Among heavily pretreated patients with relapsed/refractory diffuse large B cell lymphoma in the second line, CD19 CAR T-cell therapy improved event-free survival by up to ___% over chemotherapy plus stem cell transplantation.

20%

40%

60%

80%

4 / 5

Which approach offers the best clinical outcome for a patient with relapsed/refractory diffuse B-cell lymphoma in the third-line setting after chemoimmunotherapy?

Loncastuximab tesirine

Polatuzumab vedotin ± bendamustine/rituximab

Chimeric antigen receptor T-cell (CAR-T) therapy

Tafasitamab + lenalidomide

5 / 5

Which of the following is the target protein of the approved CAR T-cell therapy products for relapsed/refractory diffuse B-cell lymphoma?

CD11

CD19

CD22

BCMA (B-cell maturation antigen)

Your score is

The average score is 66%

0%